The first purpose of this study was to develop a diagnostic system for TP53 signature through an analysis of 223 FFPE breast cancer specimens using nCounter and to demonstrate the robust predictive ability of TP53 signature compared to other expression profiles by analyzing RNA-seq data. This evidence concerns the gene TP53 and breast carcinoma.